Sac-TMT is a novel human TROP2 ADC with proprietary intellectual property, targeting advanced solid tumors
It's a development that marks a major step forward for patients struggling with moderate-to-severe chronic spontaneous urticaria
Centanafadine is a first-in-class norepinephrine, dopamine, and serotonin reuptake inhibitor
The trials, designed to assess whether semaglutide could slow cognitive decline, showed no significant difference compared to placebo in the progression of Alzheimer’s disease over two years
Adzynma, approved for both adults and children with cTTP, is a recombinant enzyme therapy designed to replace the deficient ADAMTS13 enzyme
The therapy -- Ryoncil (remestemcel-L-rknd) -- will be tested in adults with severe steroid-refractory acute graft-versus-host disease
AVT03 is a biosimilar of Amgen's Prolia (denosumab 60 mg/mL) and Xgeva (denosumab 70 mg/mL), which are used to treat various bone conditions
Landmark studies have shown that rapid TXA administration can significantly reduce mortality
The multibillion-dollar Maryland expansion is part of AstraZeneca’s sweeping $50 billion global investment plan
The formulation is backed by over 80 clinical trials and 200 scientific publications
Subscribe To Our Newsletter & Stay Updated
